The substantial rise in CD8+ T-cells and TCM CD8+ T-cells, coupled with the decrease in PD1+ CD8+ T-cells, indicates that FXT has a substantial impact on the anti-tumor immune response. The gene discussed is CD8A; the disease is neoplasm.